Integrated DNA Technologies (IDT), a global leader in CRISPR genome editing solutions, has entered into a licensing agreement with SeQure Dx, a company specializing in off-target analysis for gene modification customers. This agreement enhances IDT’s CRISPR portfolio, offering comprehensive solutions from research to clinical-grade manufacturing.
The licensing agreement allows IDT to support cell and gene therapy developers through all phases of their CRISPR-based therapeutic programs. It includes SeQure Dx’s GUIDE-seq technology for off-target analysis, integrated with IDT’s award-winning rhAmpSeq™ CRISPR Analysis System. Sandy Ottensmann, VP/General Manager of IDT’s Gene Writing & Editing Business Unit, emphasized the importance of delivering safer genome editing platforms as more CRISPR-based therapeutics enter clinical trials. “IDT’s expanded off-target analysis capabilities demonstrate a transformational shift to support cell and gene therapy developers in their transition to the clinic, ensuring life-changing therapies are as safe as possible,” Ottensmann said.
Dr. Keith Joung, Scientific Founder of SeQure Dx, highlighted the synergy between SeQure’s and IDT’s technologies, stating, “Combining SeQure’s and IDT’s innovative technologies will enhance precision and safety in gene editing, bringing transformative solutions to researchers and patients worldwide.”
The agreement grants IDT access to SeQure Dx’s GUIDE-seq technology, a widely used next-generation sequencing-based off-target analysis tool developed by Keith Joung’s team at Massachusetts General Hospital. GUIDE-seq is pivotal for identifying double-stranded breaks in genome editing, aiding the development of CRISPR-focused therapeutics.
In response to increased demand for cell and gene therapy components, IDT recently opened a therapeutic oligonucleotide manufacturing facility in the U.S. The facility supports high-quality production for CGMP/Q7 services, critical for accelerating the path to clinic for developers.
IDT’s proprietary rhAmpSeq CRISPR Analysis System, regulatory expertise, and dedicated support team provide a unique, integrated solution for CRISPR therapeutic development. Launched in 2021, the rhAmpSeq CRISPR Analysis System offers end-to-end characterization of on- and off-target genome editing events, endorsed by renowned scientists and gaining popularity for its robust analysis capabilities in CRISPR research.
